About hoth therapeutics inc - HOTH
Hoth Therapeutics, Inc. engages in the development of new generation therapies for dermatological disorders. Its product pipeline focuses on potential treatments for indications including atopic dermatitis (also known as eczema), chronic wounds, psoriasis, asthma, and acne. It offers the BioLexa Platform, a drug compound platform for the treatment of eczema. The company was founded by Robbie Knie, Matthew D. Eitner, and James Ahern on May 16, 2017 and is headquartered in New York, NY.
HOTH At a Glance
Hoth Therapeutics, Inc.
1177 Avenue of the Americas
New York, New York 10036
| Phone | 1-646-756-2997 | Revenue | 0.00 | |
| Industry | Pharmaceuticals: Major | Net Income | -12,469,302.00 | |
| Sector | Health Technology | Employees | 6 | |
| Fiscal Year-end | 12 / 2026 | |||
| View SEC Filings |
HOTH Valuation
| P/E Current | N/A |
| P/E Ratio (with extraordinary items) | N/A |
| P/E Ratio (without extraordinary items) | N/A |
| Price to Sales Ratio | N/A |
| Price to Book Ratio | 2.497 |
| Price to Cash Flow Ratio | N/A |
| Enterprise Value to EBITDA | -0.668 |
| Enterprise Value to Sales | N/A |
| Total Debt to Enterprise Value | 0.001 |
HOTH Efficiency
| Revenue/Employee | N/A |
| Income Per Employee | -2,078,217.00 |
| Receivables Turnover | N/A |
| Total Asset Turnover | N/A |
HOTH Liquidity
| Current Ratio | 4.685 |
| Quick Ratio | 4.685 |
| Cash Ratio | 4.301 |
HOTH Profitability
| Gross Margin | N/A |
| Operating Margin | N/A |
| Pretax Margin | N/A |
| Net Margin | N/A |
| Return on Assets | -162.825 |
| Return on Equity | -191.399 |
| Return on Total Capital | -202.541 |
| Return on Invested Capital | -191.359 |
HOTH Capital Structure
| Total Debt to Total Equity | 0.092 |
| Total Debt to Total Capital | 0.092 |
| Total Debt to Total Assets | 0.075 |
| Long-Term Debt to Equity | N/A |
| Long-Term Debt to Total Capital | N/A |